Key result
Administration of the CXCR2 inhibitor SB225002 to spontaneously hypertensive rats prevented and reversed atrial fibrillation development and atrial remodelling compared with vehicle treatment.
Why the study?
The role of the chemokine-receptor CXCR2 in the pathogenesis of hypertensive AF remained unclear.
Does the CXCR2 inhibitor SB225002 prevent or reverse atrial fibrillation in spontaneously hypertensive rats?
Does the CXCR2 inhibitor SB225002 prevent or reverse atrial fibrillation in spontaneously hypertensive rats?
Inhibition of CXCR2 with SB225002 prevents and reverses atrial fibrillation and associated atrial remodeling in a hypertensive rat model.
No takes yet. Share an insight, caveat, or question.
May support CXCR2 inhibition in hypertensive AF models; hypothesis-generating, human trials needed.
Zhang et al. (2020) studied Hypertensive atrial fibrillation. CXCR2 inhibitor SB225002 vs. vehicle treatment was evaluated on AF inducibility and duration, atrial remodelling, recruitment of macrophages, superoxide production and conduction abnormalities. Administration of the CXCR2 inhibitor SB225002 to spontaneously hypertensive rats prevented and reversed atrial fibrillation development and atrial remodelling compared with vehicle treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: